FDA Approved: ARGATROBAN — Supplemental Application (Mylan Institutional LLC)

View source ↗

Summary

The FDA approved a supplemental application for Argatroban from Mylan Institutional LLC under ANDA 202626, expanding the use of this generic anticoagulant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heparin-induced Thrombocytopenia
• Thromboembolism

Drugs mentioned

• Argatroban (argatroban)

Snippet

SUPPL AP for ARGATROBAN (ARGATROBAN)